A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals

J Sex Med. 2023 Jul 31;20(8):1057-1059. doi: 10.1093/jsxmed/qdad083.

Authors

Selim Cellek¹, Matthew Megson^{1

2}, Marcus M Ilg¹, David J Ralph^{1

2}

Affiliations

¹ Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, United Kingdom.
² Urology Department, University College London Hospital, London W1G 8PH, United Kingdom.

PMID: 37524687
DOI: 10.1093/jsxmed/qdad083

No abstract available

Keywords: fibroblast; fibrosis; myofibroblast; sildenafil; tadalafil; tamoxifen; vardenafil.

MeSH terms

Humans
Male
Penile Induration* / drug therapy
Phosphodiesterase 5 Inhibitors* / pharmacology
Phosphodiesterase 5 Inhibitors* / therapeutic use
Sildenafil Citrate
Tadalafil
Tamoxifen / therapeutic use
Triazines / pharmacology
Vardenafil Dihydrochloride / therapeutic use

Substances

Phosphodiesterase 5 Inhibitors
Tamoxifen
Sildenafil Citrate
Tadalafil
Vardenafil Dihydrochloride
Triazines